LM

At ASCO 2024, Treos Bio Reports Key Survival Results for Chemo-Free Regimen of PolyPEPI1018 Peptide Immunotherapy and Roche’s PD-L1 Inhibitor in Late-Stage Colorectal Cancer

Retrieved on: 
Montag, Juni 3, 2024
Survival, Biomarker, Safety, Colorectal cancer, ASCO, RECIST, Patient, Activity, DCR, Progression-free survival, Data science, LM, IC, Annual general meeting, Cancer, TILS, Society, Clinical professor, Immunology, Immunogenicity, Immunotherapy, MSS, NLM, Mayo Clinic, Tumor microenvironment, PFS, Incidence, CRC, Liver disease, Clinical research, Biopsy, Neoplasm, Pharmaceutical industry

LONDON and BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Treos Bio Limited, a clinical-stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, today announced the presentation of results from its phase 2 OBERTO-301 study of the company’s lead product candidate, PolyPEPI1018, in combination with atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer (MSS mCRC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Secondary endpoints include objective response rate, duration of response, progression-free survival, and overall survival.
  • Safety and Tolerability: PolyPEPI1018 in combination with atezolizumab was well tolerated, with no unexpected toxicities or serious adverse events related to treatment.
  • Hubbard et al, Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: An Open-Label, Multicenter, Phase Ib Study.
  • Eng et al, Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial.

OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

Retrieved on: 
Montag, Juni 3, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Cancer, ODD, FTD, Pediatric Oncology Group, Patient, Immunotherapy, EFS, Listeria, Children's Oncology Group, ADC, Listeria monocytogenes, Metastasis, Clinical trial, OS, HER2, Quality of life, FDA, Rated R, Learning, Treatment, Survival, Primary tumor, LM, Recurrence, Neoplasm, Pharmaceutical industry

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced a positive clinical update for AOST-2121 ( NCT04974008 ), its ongoing Phase 2b clinical trial of its immunotherapy OST-HER2 (OST31-154) in patients with resected, recurrent osteosarcoma.

Key Points: 
  • OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, today announced a positive clinical update for AOST-2121 ( NCT04974008 ), its ongoing Phase 2b clinical trial of its immunotherapy OST-HER2 (OST31-154) in patients with resected, recurrent osteosarcoma.
  • This treatment generates T cells that can eliminate or slow potential micrometastases that can grow into recurrent osteosarcoma.
  • AOST-2121 has achieved full enrollment of 41 patients treated with OST-HER2 at 21 clinical trial sites across the United States.
  • No novel therapeutic interventions have improved the clinical outcomes for patients with resected, recurrent osteosarcoma in over 40 years.

Lantronix to Showcase AI-Driven Out-Of-Band Management Solutions at Cisco Live

Retrieved on: 
Donnerstag, Mai 30, 2024
SLC, USB, Glass, Internet of things, Control center, AAA, LM, LTE, EMG, Cisco, Video game

IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions, today announced that it will do live demos of its AI-driven out-of-band management solutions at booth 4875 at Cisco Live held June 2–6, 2024, in Las Vegas.

Key Points: 
  • IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions, today announced that it will do live demos of its AI-driven out-of-band management solutions at booth 4875 at Cisco Live held June 2–6, 2024, in Las Vegas.
  • Its innovative solutions for out-of-band environments utilize rules-based AI to recover and mitigate network infrastructure automatically, including reliable and secure access to remote gear during an outage.
  • “At Cisco Live, we're excited to showcase our innovative solutions that empower our customers to utilize AI-driven decision-making to make their networks more secure and reliable while automating routine tasks, enabling network admins to focus on other responsibilities,” said Mathi Gurusamy, chief strategy officer at Lantronix.
  • Being shown at Cisco Live are:
    LM83X , delivering AI-driven out-of-band management of 8–104 devices over serial console in a scalable and robust console server with dual power inputs.

LM Funding America, Inc. Achieves Over 105% Year-Over-Year Revenue Growth to $4.7 Million and Generated $1.9 Million of Net Income for the First Quarter of 2024

Retrieved on: 
Donnerstag, Mai 16, 2024
Investment, Mining, Telephone, Sale, BTC, Total, Growth, LM, ASU, Cryptocurrency

TAMPA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a cryptocurrency mining and technology-based specialty finance company, today provided a business update and reported financial results for the three months ended March 31, 2024.

Key Points: 
  • This success has resulted in a 105% increase in our revenue compared to the first quarter of 2023.
  • Richard Russell, Chief Financial Officer of LM Funding, further noted, "We ended the quarter with cash plus Bitcoin, valued as of March 31, 2024, of approximately $12.5 million.
  • Our working capital stood at $12.7 million as of March 31, 2024, and the equity of LM Funding shareholders was $38.5 million, or $15.43 per share.
  • Total LM Funding stockholders’ equity was approximately $38.5 million, or $15.43 per share, as of March 31, 2024.

Calling All Creatives: Fujifilm Announces FUJIFILM X-T50 Mirrorless Digital Camera and FUJINON XF16-50mmF2.8-4.8 R LM WR Lens

Retrieved on: 
Donnerstag, Mai 16, 2024
Cloud, Camera, CAD, OIS, XF, Element, Signal-to-noise ratio, MSRP, Motorcycle, Weather, Fujifilm, Animal, IBIS, Miniaturization, Bird, LM, ISO, Hand, Silver, Plant, Temperature, LCD, Lens, Telescopic sight

X-T50 is the latest X Series camera to integrate Frame.io’s Camera to Cloud technology, joining FUJIFILM X-H2, FUJIFILM X-H2S, FUJIFILM X-T5, FUJIFILM X-S20, and FUJIFILM X100VI mirrorless digital cameras in offering the capability.

Key Points: 
  • X-T50 is the latest X Series camera to integrate Frame.io’s Camera to Cloud technology, joining FUJIFILM X-H2, FUJIFILM X-H2S, FUJIFILM X-T5, FUJIFILM X-S20, and FUJIFILM X100VI mirrorless digital cameras in offering the capability.
  • FUJINON XF16-50mmF2.8-4.8 R LM WR lens is also expected to be available in June 2024, at a Manufacturer’s Suggested Retail Price of $699.95 USD ($949.99 CAD).
  • Alongside the release of the FUJINON XF16-50mmF2.8-4.8 R LM WR lens, Fujifilm plans to introduce kits featuring this lens with its FUJIFILM X-T50, FUJIFILM X-T5, and FUJIFILM X-S20 mirrorless digital cameras, each of which feature in-body image stabilization designed to maximize the lens's performance.
  • Manufacturers Suggested Retail Price of the X-T50 kit variations will be as follows:
    FUJIFILM X-T50 with XF16-50mmF2.8-4.8 R LM WR Lens Kit: MSRP $1,799.95 USD ($2,429.99 CAD)
    FUJIFILM X-T5 with XF16-50mmF2.8-4.8 R LM WR Lens Kit: MSRP $2,099.95 USD ($2,839.99 CAD)
    FUJIFILM X-S20 with XF16-50mmF2.8-4.8 R LM WR Lens Kit: MSRP $1,699.95 USD ($2,299.99 CAD)

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
Mittwoch, Mai 15, 2024
Cancer, Neuro, Molecular imaging, Feasibility, Patient, Ependymoma, Plus Therapeutics, Treatment, SNMMI, FDA, IND, CED, Anticipation, Therapy, Trial of the century, Conference, Breast cancer, Society, Nuclear medicine, Acquisition, PSTV, Spinal cord, LM, Completeness, Safety, Meninges, Webcast, Biomarker, Annual general meeting, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent and upcoming business highlights.
  • Additional detail on the acquisition can be found here
    Strengthened management team with appointments of neuro-oncologist Andrew Brenner, M.D.
  • Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call.
  • The webcast will be available on the Company’s website for 90 days following the live call.

Yard Force Introduces New 20V Cordless Lawn Mower: A Powerful, Efficient and Versatile Solution for Easy Lawn Care

Retrieved on: 
Freitag, Mai 17, 2024
Technology, Women, Other Retail, Men, Home Goods, Family, Consumer, Retail, Consumer Electronics, Longevity, Garden, Yard, Translation, Force, LM, Landscape maintenance

Yard Force, a leading manufacturer of high-quality garden tools, is pleased to announce the launch of its latest product innovation, the Yard Force 20V Cordless Lawn Mower.

Key Points: 
  • Yard Force, a leading manufacturer of high-quality garden tools, is pleased to announce the launch of its latest product innovation, the Yard Force 20V Cordless Lawn Mower.
  • One of the standout features of the Yard Force LM C37B is its powerful 20V 2.5Ah dual battery system.
  • With the launch of the Yard Force LM C37B cordless lawn mower, Yard Force reaffirms its dedication to delivering innovative, high-quality products that meet the needs of today's homeowners.
  • The new Yard Force lawn mowers are now available online: https://www.amazon.de/dp/B0D49G12B1
    Yard Force is a leading manufacturer of high-quality garden tools.

LM Energy Announces Expansion of Northern Delaware Basin Natural Gas Gathering System

Retrieved on: 
Montag, Mai 13, 2024
Oil, Gas, Energy, Map, Lea, LM

LM Energy Holdings, LLC (LM) today announced it has entered into definitive long-term agreements with multiple top-tier producer customers to support significant expansions of its gas gathering systems in Eddy and Lea counties, New Mexico.

Key Points: 
  • LM Energy Holdings, LLC (LM) today announced it has entered into definitive long-term agreements with multiple top-tier producer customers to support significant expansions of its gas gathering systems in Eddy and Lea counties, New Mexico.
  • LM has begun constructing multiple new compressor stations and approximately 70 miles of new, large-diameter, low-and-high-pressure gas pipelines, including a 27-mile, 20-inch high-pressure pipeline that will connect the company’s existing Touchdown gas gathering system to multiple gas processing facilities near Loving, New Mexico.
  • The new high-pressure pipeline will provide over 300 million cubic feet per day (MMcf/d) of critical delivery capacity out of the North Carlsbad area.
  • “Upon completion, our system will provide our customers with much-needed flow assurance and unlock their plans to aggressively develop this extremely high-quality acreage.”
    For more information, including an updated operations map, please visit the LM Energy website .

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Retrieved on: 
Donnerstag, Mai 9, 2024
Plus Therapeutics, Northwestern University, LM, PSTV, Hematology, Breast, Lung cancer, CNS, Incidence, Patient, Acquisition, MRI, Neuro, Central nervous system, Clinical trial, Plus, Associate, Therapy, Cancer, Medical imaging

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

Key Points: 
  • Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™” and discussed potential partnering opportunities
    AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.
  • “Leptomeningeal metastases (LM) is significantly underdiagnosed because current tests such as MRI and cytology lack sensitivity,” said Priya U. Kumthekar, M.D., Associate Professor of Neurology (Neuro-oncology) and Medicine (Hematology and Oncology) at Northwestern University & The Feinberg School of Medicine.
  • Plus discussed its plan to develop the CNSide diagnostic portfolio alongside its lead radiotherapeutic candidate rhenium (Re186) obisbemeda, and to seek partnering opportunities for CNSide.
  • Plus presented topline clinical trial data from the FORESEE trial which met its primary endpoint of clinical utility for the CNSide test in 40 patients with LM due to either breast or non-small cell lung cancer; a presentation of the full analysis is planned for the August 8-10 SNO/ASCO Meeting in Denver, CO.
    “Better diagnostics for leptomeningeal metastases are a clinical imperative for these patients and will help increase the market for our lead radiotherapeutic candidate rhenium (Re186) obisbemeda,” said Dr. Marc H. Hedrick, M.D., Plus Therapeutics President and Chief Executive Officer.

American College of Lifestyle Medicine Celebrates 20th Anniversary and Announces Speakers, Presenting Sponsor for 2024 Annual CME/CE-Accredited Conference Oct. 27-30

Retrieved on: 
Donnerstag, Mai 2, 2024
Consensus, Online, Alzheimer's disease, MAS, Planning committee, Therapy, MPA, CME, American College, DOS, Certification, LM, Health, ACLM, Consensus decision-making, Conference, Person-centered therapy, Research, Loma Linda University, Nursing, MPH, Food, FACPM, RN, ACO, Medicine, Conditional sentence, Practitioner, Prometric, Social, MBA, Student, Human, FACP, Pharmacist, Livestreaming

ST. LOUIS, May 2, 2024 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) today announced the keynote speaker lineup for its 2024 Lifestyle Medicine Annual Conference, set for October 27-30, in person at the Rosen Shingle Creek Resort in Orlando, Fla., with virtual registration also available. The hybrid event will showcase how lifestyle medicine is changing the paradigm of medical education and clinical practice to restore health for those living with chronic disease. Presenting sponsor for the event is Lore Health, a leading lifestyle-medicine focused accountable care organization (ACO).

Key Points: 
  • The American College of Lifestyle Medicine (ACLM) today announced the keynote speaker lineup for its 2024 Lifestyle Medicine Annual Conference, set for October 27-30, in person at the Rosen Shingle Creek Resort, Orlando, Fla., as well as virtually.
  • ST. LOUIS, May 2, 2024 /PRNewswire-PRWeb/ -- The American College of Lifestyle Medicine (ACLM) today announced the keynote speaker lineup for its 2024 Lifestyle Medicine Annual Conference, set for October 27-30, in person at the Rosen Shingle Creek Resort in Orlando, Fla., with virtual registration also available.
  • Concurrent sessions for the in-person event will be offered in four tracks : Application of Lifestyle Medicine; Allied Health Providers in Lifestyle Medicine; Healthcare Transformation Through Lifestyle Medicine; and Current Issues in Healthcare.
  • For more information about the conference or to register, visit Lifestyle Medicine Conference 2024 - American College of Lifestyle Medicine .